Table 2 Assessment of harm described in reports of randomized controlled trials assessing stent treatment for coronary diseases by type of stent
| Â | All reports | Drug-eluting stent | Polymer-coating stent | Bare metal stent |
|---|---|---|---|---|
| Â | N = 132 | N = 64 | N = 19 | N = 41 |
| Â | N (%) | N (%) | N (%) | N (%) |
Assessment of harm | Â | Â | Â | Â |
   - Nature of adverse events systematically collected when considering |  |  |  |  |
- All adverse events | 110 (83) | 50 (78) | 16 (84) | 39 (95) |
- Events other than MAC(C)E1 | 63 (48) | 22 (34) | 8 (42) | 16 (39) |
   - Mode of data collection provided when considering |  |  |  |  |
- All adverse events | 29 (22) | 17 (27) | 5 (26) | 6 (15) |
- Events other than MAC(C)E1 | 13 (10) | Â | Â | Â |
Definition of expected adverse event | 47 (36) | 27 (42) | 2 (11) | 14 (34) |
Assessment by an adjudication committee | 46 (35) | 35 (55) | 4 (21) | 7 (17) |
Length of follow-up specified | 95 (72) | 52 (81) | 11 (58) | 32 (78) |
   - < 1 month | 3 (2) | 1 (2) | 0 | 2 (5) |
   - 6 months | 32 (24) | 14 (22) | 7 (37) | 11 (27) |
   - 7–11 months | 27 (20) | 21 (33) | 1 (5) | 5 (12) |
   - 12 months | 28 (21) | 14 (22) | 1 (5) | 13 (32) |
   - > 12 months | 5 (4) | 2 (3) | 2 (11) | 1 (2) |
No duration specified | 29 (22) | 12 (19) | 8 (42) | 9 (22) |